Fotoula Stroumpos

Elesclomol-copper treatment rescues developmental defects
in a zebrafish disease model of Ctr1 deficiency
Copper (Cu) is an essential cofactor for enzymes that support diverse cellular functions, including mitochondrial respiration, pigment production, and iron homeostasis. Mutations in CTR1, an evolutionarily conserved Cu transporter, have been recently identified in patients with a fatal infantile disorder; however, the pathogenicity of these mutations and the role of CTR1 in development have remained obscure. Here, we used a yeast heterologous expression system to validate the pathogenicity of patient-derived CTR1 variants and generated a zebrafish ctr1 knockout to define the role of CTR1 in organismal development. Comprehensive analysis of ctr1 null zebrafish revealed hypopigmentation, systemic Cu deficiency, and reduced abundance of COX1, a mitochondrial cuproprotein. These biochemical defects were accompanied by severely impaired growth, high mortality, and a shortened lifespan, with knockout animals dying before reaching sexual maturity. Chronic treatment with the Cu ionophore elesclomol-Cu (ES-Cu) restored Cu homeostasis and rescued survival and development, whereas clinically used Cu-histidine failed to provide benefit. Notably, transient withdrawal of ES-Cu in adult ctr1 null females produced offspring with a marked notochord defect, which was fully corrected by ES-Cu supplementation at fertilization, demonstrating a critical maternal Cu requirement during early embryogenesis. Finally, untargeted metabolomics of ctr1 null larvae ± ES-Cu identified previously unrecognized Cu-dependent metabolic pathways, including biopterin and vitamin B metabolism. Together, these findings establish CTR1 as essential for vertebrate development, identify ES-Cu as an effective therapeutic strategy for CTR1-associated Cu deficiency, and define metabolic signatures of Cu deprivation.